The Full Wiki

More info on Ladostigil

Ladostigil: Wikis

Advertisements

Note: Many of our articles have direct quotes from sources you can cite, within the Wikipedia article! This article doesn't yet, but we're working on it! See more info or our list of citable articles.

Encyclopedia

From Wikipedia, the free encyclopedia

Ladostigil
Systematic (IUPAC) name
[(3R)-3-(prop-2-ynylamino)indan-5-yl]- N-propylcarbamate
Identifiers
CAS number  ?
ATC code  ?
PubChem 208907
ChemSpider 181005
Chemical data
Formula C16H20N2O2
Mol. mass 272.34 g/mol
Synonyms [N-propargyl-(3R)-aminoindan-5yl]-N-propylcarbamate
Pharmacokinetic data
Bioavailability  ?
Metabolism  ?
Half life  ?
Excretion  ?
Therapeutic considerations
Pregnancy cat.  ?
Legal status Uncontrolled
Routes  ?

Ladostigil (TV3326) is a novel neuroprotective agent being investigated for the treatment of neurodegenerative disorders like Alzheimer's disease, Lewy body disease, and Parkinson's disease.[1] It acts as a reversible acetylcholinesterase and butyrylcholinesterase inhibitor, and an irreversible monoamine oxidase B inhibitor, and combines the mechanisms of action of older drugs like rivastigmine and rasagiline into a single molecule.[2][3] In addition to its neuroprotective properties, ladostigil enhances the expression of neurotrophic factors like GDNF and BDNF, and may be capable of reversing some of the damage seen in neurodegenerative diseases via the induction of neurogenesis.[4] Ladostigil also has antidepressant effects, and may be useful for treating comorbid depression and anxiety often seen in such diseases as well.[5][6]

See also

References

  1. ^ Weinstock M, Bejar C, Wang RH, et al. (2000). "TV3326, a novel neuroprotective drug with cholinesterase and monoamine oxidase inhibitory activities for the treatment of Alzheimer's disease". Journal of Neural Transmission. Supplementum (60): 157–69. PMID 11205137.  
  2. ^ Weinreb O, Mandel S, Bar-Am O, et al. (January 2009). "Multifunctional neuroprotective derivatives of rasagiline as anti-Alzheimer's disease drugs". Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics 6 (1): 163–74. doi:10.1016/j.nurt.2008.10.030. PMID 19110207. http://linkinghub.elsevier.com/retrieve/pii/S1933-7213(08)00226-2.  
  3. ^ Weinstock M, Luques L, Bejar C, Shoham S (2006). "Ladostigil, a novel multifunctional drug for the treatment of dementia co-morbid with depression". Journal of Neural Transmission. Supplementum (70): 443–6. PMID 17017566.  
  4. ^ Weinreb O, Amit T, Bar-Am O, Youdim MB (December 2007). "Induction of neurotrophic factors GDNF and BDNF associated with the mechanism of neurorescue action of rasagiline and ladostigil: new insights and implications for therapy". Annals of the New York Academy of Sciences 1122: 155–68. doi:10.1196/annals.1403.011. PMID 18077571. http://www3.interscience.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=0077-8923&date=2007&volume=1122&spage=155.  
  5. ^ Weinstock M, Poltyrev T, Bejar C, Youdim MB (March 2002). "Effect of TV3326, a novel monoamine-oxidase cholinesterase inhibitor, in rat models of anxiety and depression". Psychopharmacology 160 (3): 318–24. doi:10.1007/s00213-001-0978-x. PMID 11889501. http://dx.doi.org/10.1007/s00213-001-0978-x.  
  6. ^ Weinstock M, Gorodetsky E, Poltyrev T, Gross A, Sagi Y, Youdim M (June 2003). "A novel cholinesterase and brain-selective monoamine oxidase inhibitor for the treatment of dementia comorbid with depression and Parkinson's disease". Progress in Neuro-psychopharmacology & Biological Psychiatry 27 (4): 555–61. doi:10.1016/S0278-5846(03)00053-8. PMID 12787840. http://linkinghub.elsevier.com/retrieve/pii/S0278-5846(03)00053-8.  
Advertisements

Advertisements






Got something to say? Make a comment.
Your name
Your email address
Message